Understanding the Deadly Cancer Gap

Over the past 40 years, cancer survival rates have improved significantly for some cancers, including breast, prostate and melanoma. Advances in research, screening and treatment have transformed outcomes and saved countless lives.

Yet this progress has not been shared equally. Six cancers, lung, pancreatic, liver, brain, oesophageal and stomach, remain just as deadly today as they were decades ago. Together, these less survivable cancers account for around half of all deaths from common cancers, despite representing only a quarter of diagnoses.

For patients, the reality is stark. The average five-year survival rate across these cancers is just 16%, meaning only one in six people diagnosed will still be alive five years later. This disparity is known as the deadly cancer gap.

The Lung Cancer Challenge

Among these cancers, lung cancer represents both the greatest challenge and the greatest opportunity for change. It is one of the most commonly diagnosed cancers worldwide and remains the leading cause of cancer death in the UK.

The reason is tragically simple: lung cancer is often detected too late. Early-stage lung cancer typically causes few or no symptoms, meaning many people are only diagnosed once the disease has progressed to an advanced stage, where treatment options are limited and outcomes are poor.

The Power of Early Detection

The contrast between early and late diagnosis could not be clearer. When lung cancer is caught at Stage 1, five-year survival rates can reach 70–90%. By Stage 4, survival falls to below 10%.

This dramatic difference highlights a fundamental fact in cancer care: timing is everything. Earlier diagnosis not only saves lives, but can also reduce the need for aggressive treatments, improve quality of life for patients, and ease pressure on healthcare systems.

A Path Forward

Closing the deadly cancer gap depends on progress in three critical areas: more research, better treatments and, crucially, earlier diagnosis. Improving how lung cancer is detected is one of the most powerful ways to shift outcomes.

At Cizzle Biotechnology, early detection sits at the heart of our mission. We are developing non-invasive, innovative blood-based diagnostic test designed to identify lung cancer at its earliest, most treatable stages, before symptoms appear and when intervention can make the greatest difference.

Changing Outcomes, Saving Lives

Closing the deadly cancer gap is not just about improving statistics. It is about people, patients, families and communities affected by devastating diagnoses each year. By focusing on early detection and continued innovation, lung cancer does not have to remain one of the least survivable cancers.

With the right tools and sustained commitment, we can help transform lung cancer from a disease detected too late into one caught early, giving more people the chance to survive and thrive.

One test. Earlier detection. More lives saved.